Aeropay | $20,000,000 | (May 17, 2024)
Bedrock Materials | $9,000,000 | (May 17, 2024)
OTPLESS | $3,500,000 | (May 17, 2024)
CellVoyant
United Kingdom
- Bristol, England
- 27/02/2024
- Seed
- $9,644,590
CellVoyant is an AI-first biotechnology company with a mission to create novel stem cell-based therapies for chronic diseases. Our technology uses AI-first live cell imaging to predict and optimise stem cell differentiation, to controllably manufacture any cell and tissue in the body at scale. CellVoyant is built on foundational work from the Carazo Salas lab at the University of Bristol.
We’re working at the exciting intersection of cell biology, computer vision, engineering, and machine learning to industrialise next-generation science from research into the real world.
Our mission is bold and ambitious and we have the best investors behind us from day 1. We’re backed by venture capital firms who were the earliest investors in AI pioneer DeepMind, the two leading AI-first drug discovery companies, Exscientia and Recursion, and self-driving challenger Wayve. We’re also supported by the founder/CEO of Abcam, which pioneered the antibody business.
- Industry Biotechnology
- Website https://cellvoyant.com/
- LinkedIn https://www.linkedin.com/company/cellvoyant/
Related People
Rafael E. Carazo SalasFounder
United Kingdom -
Greater Bristol Area
Big Data & Stem Cell Scientist working to make predictive, data driven and stem cell therapeutics realities. Professor @BristolUni formerly @Cambridge_Uni, Founder & CEO of CellVoyant.
ekko | $2,500,000 | (May 17, 2024)
Watershed Health | $13,600,000 | (May 17, 2024)
HEPHAISTOS-Pharma | $11,189,199 | (May 17, 2024)
Keyper | $4,000,000 | (May 17, 2024)
c/side | $1,700,000 | (May 17, 2024)
SINE Digital | $2,500,000 | (May 17, 2024)
Angel AI | $4,750,000 | (May 17, 2024)
InstaAstro | $2,300,000 | (May 17, 2024)
Fay | $25,000,000 | (May 16, 2024)